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Abstract
Background: Studies suggested that interleukin-18 (IL-18)/interleukin-10 (IL-10) ratio is 
an independent predictor of adverse cardiovascular events in patients with acute coronary syn-
dromes (ACS). In this study we aimed to evaluate the predictive significance of IL-18/IL-10 for 
the occurrence of ACS in patients with stable angina pectoris (SAP) over a 40-month follow-up.
Methods: The IL-18, IL-10 levels of 257 patients with SAP were determined by Enzyme-
-Linked Immunosorbent Assay (ELISA). Two hundred and fifty-two patients, 42 of whom had 
ACS and 210 were event-free, were divided into two groups according to the presence or absence 
of the occurrence of ACS during the 40-month follow-up.
Results: Plasma IL-18 and IL-18/IL-10 ratios were both significantly higher (p = 0.001 and 
p = 0.044, respectively) among patients with ACS, however, IL-10 level was lower (p = 0.046)  
compared to the patients without ACS. The elevation of plasma IL-18/IL-10 ratio and the 
number of coronary artery lesions made the advantage ratio of ACS in patients with SAP 
increase 4.242 times and 1.942 times (p = 0.000 and p = 0.011, respectively).
Conclusions: Plasma IL-18 and IL-10 levels in patients with SAP are closely related to the 
occurrence of ACS, elevated IL-18/IL-10 ratio has a positive predictive value for the occurrence 
of ACS in patients with SAP. (Cardiol J 2014; 21, 1: 83–88)
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Introduction
The formation of complete or incomplete 
occlusive thrombus as a result of the erosion or 
rupture of vulnerable plaque is the pathological 
basis of acute coronary syndrome (ACS). Our 
long-term clinical practice suggests that although 
patients have different clinical manifestations, 
the underlying pathophysiological changes are 
very similar, that is the coronary atherosclerosis 
plaque transforms into vulnerable plaques, then 
ruptures and leads to the formation of thrombosis. 
Obviously, the rupture of coronary artery vulne-
rable plaque is one of the most important links in 
the occurrence of ACS. A number of studies [1–3] 
shows that inflammation plays an important role in 
the formation and rupture of vulnerable plaques. 
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A variety of inflammatory cells and secreted pro-
-inflammatory cytokines make the fibrous cap of 
the plaque become thinner and the lipid core of 
the plaque become larger, leading to the formation 
of vulnerable plaque phenotype prone to rupture.
Interleukin-18 (IL-18) is a multi-performance 
pro-inflammatory cytokine, which plays an impor-
tant role in inflammatory reaction [4]. IL-18 may 
accelerate the formation of vulnerable plaques 
[5] and is closely related to the occurrence and 
prognosis of ACS [6, 7]. Interleukin 10 (IL-10) 
is a kind of an anti-inflammatory cytokine which 
can reduce the formation of atherosclerosis and 
maintain the stability of atheromatous plaques, 
which play an important role in inhibiting the oc-
currence of ACS [8, 9]. Patients with ACS show an 
imbalance between serum levels of pro- and anti-
-inflammatory cytokines. Clinical data confirm that 
[6, 10, 11] IL-18 and IL-10 have predictive values 
for the prognosis of patients with ACS, however, it 
is not yet clear if they also have predictive values 
for the occurrence of ACS in patients with stable 
angina pectoris (SAP). In this study, we detected 
the plasma IL-18, IL-10 levels in patients with 
SAP and all patients were followed up. In order to 
investigate the correlation between IL-18/IL-10 
ratio and the occurrence of ACS in patients with 
SAP, plasma IL-18/IL-10 ratio was determined as 
a correlative factor which may affect the prognosis 
of coronary heart disease (CHD).
Methods
Patient selection and follow-up
According to the definition of SAP from ACC/ 
/AHA CHD classification criteria, a total of 257 pa - 
tients (175 male and 82 female, of average age 
64.06 ± 10.46 years) with SAP were enrolled du-
ring the period of March 2007 and September 2008 
in the Vasculocardiology Deparment of General 
Hospital of Guangzhou Military Command after 
obtaining the ethical approval and informed consent 
from all of them. All patients were confirmed by 
coronary angiography, having at least one major 
vascular stenosis ≥ 50% as the standard for vascu-
lar lesion and lesion number. Of the 257 patients, 
all were confirmed by medical history, physical 
examination, laboratory examination and assistant 
examination. Patients with myocarditis, severe 
cardiac dysfunction, peripheral vascular disease, 
severe liver and kidney diseases, autoimmune 
diseases, blood diseases, inflammation infection, 
other severe systemic diseases, or patients using 
inflammation inhibitor were excluded.
Patients’ gender, age, body mass index (BMI), 
smoking history, history of diabetes, hypertension, 
and hyperlipidemia on admission were recorded, if 
not clearly, related examinations were conducted. 
Criteria for smokers are: current smokers (≥ 5 ci - 
garettes/day) or having smoking history of more 
than 10 years but quitting less than 1 year before. 
According to the Chinese dyslipidemia preven-
tion advice of 2006, hyperlipidemia diagnostic 
criteria are: hypercholesterolemia (total choleste-
rol ≥ 6.22 mmol/L and/or low-density lipoprotein 
cholesterol ≥ 4.14 mmol/L), hypertriglyceridemia 
(triglycerides ≥ 2.26 mmol/L) and combined hy-
perlipidemia. The above information, age and BMI 
were processed as data for measurement, all other 
data were processed as count data.
All patients without contraindications were 
given primary drug treatment of CHD (aspirin, 
beta receptor blocker and/or ACEI, nitrates, etc.). 
Patients with major vascular stenosis ≥ 70% were 
given percutaneous coronary intervention therapy, 
and low molecular weight heparin and/or platelet 
GP IIb/IIIa receptor antagonist, clopidogrel, etc., 
were given based on the primary drug treatment of 
CHD. Patients with diabetes received oral hypogly-
cemic or insulin hypoglycemic treatment. Patients 
who did not reach the standard of glycosylated 
hemoglobin ≥ 6.5% (Chinese Chronic Stable An-
gina Diagnosis and Treatment Guidelines of 2006), 
were closely followed up (1 time/month) and given 
more strengthening drugs. The glycosylated hemo-
globin was closely monitored until it reached the 
standard. Patients with hypertension received oral 
hypertension treatment; aged patients (over the 
age of 60) who did not reach the standard, elderly 
systolic blood pressure ≥ 150 mm Hg and non-
-elderly blood pressure ≥ 130/80 mm Hg (Chinese 
Chronic Stable Angina Diagnosis and Treatment 
Guidelines of 2006), were closely followed up 
(1 time/month) and given more strengthening 
drugs. The blood pressure was closely monitored 
until it reached the standard. Unless contraindica-
ted, patients with hyperlipidemia received statin 
treatment; patients who did not reach the standard, 
low density lipoprotein ≥ 2.6 mmol/L and/or total 
cholesterol ≥ 4.68 mmol/L (Chinese Dyslipidemia 
Control Suggestion of 2006), were closely followed 
up (1 time/month) and given more strengthening 
drugs. Lipidemia was closely monitored until it re-
ached the standard. All smoking patients received 
patient education and smoking cessation guidance 
until they quit smoking successfully.
All patients were followed up once a month af-
ter being discharged by telephone contacts, letters, 
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or visit to collect medical records up to 40 months 
(March 2007 – February 2012). The end-point 
of the study was ACS (unstable angina pectoris, 
ST-segment elevation myocardial infarction, non-
-ST-segment elevation myocardial infarction were 
included). Patients were divided into two groups 
according to the presence (group A) or absence 
(group B) of ACS during the 40 month follow-up.
IL-18 and IL-10 measurements
Fasting venous blood samples were drawn on 
the first morning after permission, 5 mL peripheral 
venous blood was placed into an ENTA-2Na anti-
coagulant tube, after centrifugation at 3000 rpm 
for 15 min, radius of 1 cm. One mL upper plasma 
was collected for biochemical examination of blood 
lipid, blood glucose and hepatorenal function. The 
residual upper plasma in EP tube was frozen in 
a –70°C refrigerator. The samples were applied by 
enzyme-linked immunosorbent assay (ELISA) kit 
(Rapidbio, Calabasas, CA, USA) and measured on 
a Biocell HT2 ELISA microplate reader, operating 
strictly according to the kit instructions.
Statistical analysis
SPSS 17.0 was used to analyze the data. Con-
tinuous variables are presented as mean ± SD, 
and categorical data are presented as percentages. 
Independent-sample t-test was used to analyze the 
mean differences between the two groups in age, 
BMI, the degree of main lesion stenosis, the plasma 
IL-18, the plasma IL-10 and IL-18/IL-10 ratio. The 
fourfold table c2 test was used to compare the diffe-
rences between the two groups in gender, smoking, 
diabetes, hypertension, and treatment methods. 
Logistic stepwise regression was used to analy-
ze the linear relationship between IL-18/IL-10, 
smoking, age, gender, diabetes, hypertension, 
hyperlipidemia, BMI, the grade of main lesion ste-
nosis, treatment methods, and occurrence of ACS. 
P < 0.05 was considered statistically significant.
Results
During the 40 month follow-up of 257 patients, 
4 cases were lost (telephone number and address 
change), 1 case had a sudden death (died of a brain 
hemorrhage). Forty-two (18.01%) patients had 
ACS, 33 patients had unstable angina pectoris, 
6 patients had ST-segment elevation myocardial 
infarction and 3 patients had non-ST-segment 
elevation myocardial infarction.
Table 1 shows that, during the follow-up, ACS 
group (group A) and non-ACS group (group B) 
had no significant differences (all p > 0.05) in age, 
gender, smoking, diabetes, hypertension, hyperli-
pidemia, BMI, the degree of main lesion stenosis, 
and treatment methods. They had significant dif-
ference in the number of coronary artery lesions 
(p = 0.005).
Table 2 shows the plasma IL-18 level. The IL-18/ 
/IL-10 ratio of group A was significantly higher than 
group B (p = 0.001 and p = 0.044, respectively). 
However, the IL-10 level of group B was higher 
than group A (p = 0.046).
The analyzed data took IL-18/IL-10 ratio, smo-
king, age, gender, diabetes, hypertension, hyper-
lipidemia, BMI, the grade of main lesion stenosis, 
and treatment methods as independent variables 
and the occurrence of ACS as dependent variable 
Table 1. Patient characteristics with or without acute coronary syndromes.
Characteristic Group A (n = 42) Group B (n = 210) c2/t p
Gender (male) 28 (66.67%) 144 (63.57%) c2 = 0.059 0.809
Mean age [years] 64.62 ± 12.03 63.85 ± 10.13 t = 0.433 0.514
Smoking 18 (42.85%) 64 (30.48%) c2 = 2.705 0.100
History of diabetes 20 (47.62%) 68 (32.38%) c2 = 3.576 0.059
History of hypertension 22 (52.38%) 87 (41.43%) c2 = 1.711 0.191
History of hyperlipidemia 20 (47.62%) 76 (32.38%) c2 = 1.938 0.164
Lesion number: 1 branch
                           2 branches







c2 = 10.562 0.005
Mean BMI [kg/m2] 25.30 ± 2.91 24.14 ± 3.03 t = 2.080 0.860
Main lesion stenosis [%] 74.88 ± 11.45 71.90 ± 12.69 t = 1.411 0.330
Treatment (stenting) 26 (61.90%) 117 (55.71%) c2 = 1.921 0.166
BMI — body mass index
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for logistic stepwise regression. From Table 3 we 
found that the elevation of plasma IL-18/IL-10 ratio 
and the number of coronary artery lesions made the 
advantage ratio of ACS in patients with SAP increase 
up to 4.242 (p = 0.000) and 1.942 (p = 0.011) 
times, respectively. Other factors were not signi-
ficantly associated with the occurrence of ACS in 
patients with SAP (all p > 0.05).
Discussion
To our current knowledge, the main pathophy-
siological processes of ACS are the rupture, ulcers 
of vulnerable plaques and thus thrombus formation, 
leading to a series of clinical syndromes. Vulnerable 
plaque means all the atherosclerotic lesions which 
are prone to thrombosis, and may have a rapid pro-
gress to become a sin plaque. Inflammation not only 
promotes the occurrence of atherosclerosis and 
participates in the formation of vulnerable plaque 
[1–3], but also promotes the occurrence of ACS. As 
a pro-inflammatory cytokine, IL-18 plays a central 
role in the inflammatory reaction [4], accelerating 
atherosclerosis progress, promoting atheroscle-
rotic plaque transforming into vulnerable plaque 
phenotype which would make the occurrence of 
ACS [12–14]. IL-10 is a major anti-inflammatory 
cytokine, which can inhibit the activity of inflam-
matory cells and down-regulate the expression 
and biological activity of inflammatory cytokines, 
thus inhibiting the occurrence and development of 
ACS [8, 14]. From our currently presented data, it 
is evident that, on one hand, IL-18/IL-10 ratio can 
reflect the body’s inflammatory state, yet on the 
other hand, it is closely related to the occurrence 
of ACS. Clinical data showed that [10, 14] IL-18/ 
/IL-10 ratio had predictive value for the prognosis 
of ACS. In view of the role of IL-18 and IL-10 in 
the occurrence of ACS in patients with SAP, we 
speculate that the IL-18/IL-10 ratio should have 
a certain degree of clinical significance in prognosis 
of ACS in patients with SAP, however, the clinical 
data is of shortage. Here, in this study, IL-18 and 
IL-10 levels in patients with SAP were determined 
during a 40-month follow-up and were further in-
cluded as the correlative factors that may indicate 
the prognosis of CHD.
The results showed that during the follow-up 
of 257 patients, ACS group and non-ACS group had 
no significant differences in age, gender, smoking, 
diabetes, hypertension, hyperlipidemia, BMI, the 
degree of main lesion stenosis, and treatment 
Table 3. Correlation factors analysis of the occurrence of acute coronary syndromes in patients with 
stable angina pectoris.
Correlative factors P OR SE
IL-18/IL-10 0.000 4.242 0.279
Age 0.498 1.013 0.019
Gender 0.729 0.864 0.422
Smoking 0.224 1.635 0.404
Diabetes 0.270 1.565 0.406
Hypertension 0.526 1.291 0.402
Hyperlipidemia 0.764 1.132 0.412
Body mass index 0.214 1.090 0.086
Lesion number 0.011 1.942 0.664
Degree of MLS 0.156 1.037 0.037
Treatment 0.509 0.654 0.644
OR — odds ratio; SE — standard error of mean; MLS — main lesion stenosis
Table 2. Plasma interleukin (IL)-18, IL-10, and IL-18/IL-10 levels in patients with or without acute  
coronary syndromes (mean ± SD).
Group A (n = 42) Group B (n = 210) t p
IL-18 [ng/L] 221.16 ± 78.30 170.27 ± 50.84 5.350 0.001
IL-10 [ng/L] 99.60 ± 35.17 117.76 ± 38.94 2.801 0.046
IL-18/IL-10 2.32 ± 0.73 1.57 ± 0.62 6.968 0.044
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methods. The results also showed that the above 
factors were not significantly associated with 
the occurrence of ACS in patients with SAP. 
However, the number of the coronary lesions is 
significantly higher in SAP patients with ACS 
than the SAP patients without ACS. Logistic 
regression analysis results also suggested that 
multivessel lesion elevated 1.942 times the risk 
of the occurrence of ACS in patients with SAP, 
which suggested that multivessel lesion was one 
of the risk factors for the occurrence of ACS in 
patients with SAP.
Compared to the patients without ACS, the 
plasma IL-18 level is significantly increased in 
patients with ACS. It suggests that IL-18 may 
promote the occurrence of ACS in patients with 
SAP, which is similar to Nishihira’s findings [15]. 
The mechanism of vulnerable plaque formation 
promoted by IL-18 may be: (1) IL-18 stimulates the 
release of a variety of pro-inflammatory mediators 
(such as TNF, IL-1b, IL-6, and iNOS etc.). These 
inflammatory factors, promote the macrophage apo-
ptosis in atherosclerotic plaque [16–18], increase 
the lipid core in plaque; (2) macrophages activated 
by IL-18 can secrete matrix metalloproteinase and 
collagen, which can make the fibrous cap become 
thinner [12]. The current results of this study 
showed that the plasma IL-10 level in patients with 
ACS was lower than in those without ACS, sugge-
sting that IL-10 may suppress the occurrence of 
ACS. The mechanism may be related to its strong 
anti-inflammatory effect to maintain the stability 
of the atherosclerotic plaque.
Since IL-18 is the important pro-inflammatory 
cytokine and IL-10 is the pivotal anti-inflammatory 
cytokine conversely, the IL-18/IL-10 ratio can 
reflect the body’s inflammatory activity state to 
a certain extent. Our results revealed that IL-18/ 
/IL-10 ratio was markedly higher in patients with 
ACS than those without ACS. Further logistic 
stepwise regression analysis showed that plasma 
IL-18/IL-10 ratio made the advantage ratio of the 
occurrence of ACS in patients with SAP increase 
4.242 times; other factors, except for the number 
of coronary artery lesion, had no significant corre-
lation with the occurrence of ACS in patients with 
SAP, suggesting that the enhanced body inflamma-
tory activity and IL-18/IL-10 ratio as a predictive 
factor for the occurrence of ACS in patients with 
SAP. In recent years some studies have shown [9] 
IL-18/IL-10 ratio is an independent predictor of 
recurrent cardiovascular events in patients with 
ACS. Our study extends the view that IL-18 and 
IL-10 may play an important role in the occurrence 
and development of ACS.
Conclusions
In conclusion, plasma levels of IL-18, IL-10 
in patients with SAP are closely related to the 
occurrence of ACS and IL-18/IL-10 ratio has some 
predictive value for the occurrence of ACS in 
patients with SAP. Therefore, in clinical practice, 
conventional detection of plasma levels of IL-18 
and IL-10 in patients with SAP can be applied as 
a risk assessment method for the occurrence of ACS 
in patients with SAP. Moreover, the ratio has posi-
tive significance in the treatment of patients whom 
have increased IL-18/IL-10 ratio. This study may 
provide a new insight into the clinical treatment 
of ACS in patients with SAP.
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